Abstract
CD13 is commonly expressed in hematopoietic malignancies of myelomonocytic origin and has less commonly been described in lymphoid neoplasms, including acute lymphoblastic leukemia, B‐cell lymphoproliferative disorders, and plasma cell malignancies. Aberrant CD13 expression has rarely been described in KP‐1 (CD68)‐positive large‐cell lymphomas. However, CD13 positivity has not previously been described in a case of CD30+ (ALK‐1+) anaplastic large‐cell lymphoma of presumed null‐cell origin without histiocytic differentiation. The purpose of this case report is to describe a CD30+ anaplastic large‐cell lymphoma of presumed null‐cell origin with aberrant expression of CD13. The case illustrates the unique usefulness of immunophenotypic and molecular techniques in establishing the correct diagnosis. The case was referred with a diagnosis of “rule out granulocytic sarcoma versus megakaryocytic malignancy” due to the morphology and a limited flow cytometric immunophenotypic (FCI) panel that had been performed and revealed expression of CD45, HLA‐DR, and CD13. Subsequent morphologic review at our institution combined with an expanded FCI panel established the diagnosis. The differential diagnosis of a CD13+ hematopoietic malignancy should include this entity. The prognostic significance of this finding has yet to be determined. J. Clin. Lab. Anal. 14:299–304, 2000. © 2000 Wiley‐Liss, Inc.
Keywords: CD13, CD30+ lymphoma, flow cytometry, immunohistochemistry
REFERENCES
- 1. Look AT, Peiper SC, Rebentisch MB, Ashmun RA, Roussel MF, Rettenmier CW, Sherr CJ. 1985. Transfer and expression of the gene encoding a human myeloid membrane antigen (gp150). J Clin Invest 75:569–579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Griffin JD, Ritz J, Nadler LM, Schlossman SF. 1981. Expression of myeloid differentiation antigen on normal and malignant myeloid cells. J Clin Invest 68:932–941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Griffin JD, Ritz J, Beveridge RP, Liton JM, Daley JF, Schlossman SF. 1983. Expression of MY7 antigens on myeloid precursor cells. Int J Cell Cloning 1:33–48. [DOI] [PubMed] [Google Scholar]
- 4. Look AT, Ashmun RA, Shapiro LH, Peiper SC. 1989. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 83:1299–1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Hogg N, Horton MA. 1987. Myeloid antigens: new and previously defined clusters In: McMichael AJ, Beverley PCL, Cobbold S, et al., editors. Leucocyte typing. III. White cell differentiation antigens. Oxford: Oxford University Press; p 576–621. [Google Scholar]
- 6. Mechtersheimer G, Moller P. 1990. Expression of aminopeptidase N (CD13) in mesenchymal tumors. Am J Pathol 137:1215–1222. [PMC free article] [PubMed] [Google Scholar]
- 7. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. 1984. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8:521–524. [DOI] [PubMed] [Google Scholar]
- 8. Drexler HG, Minowada J. 1986. The use of monoclonal antibodies for the identification and classification of acute myeloid leukemias. Leuk Res 10:279–290. [DOI] [PubMed] [Google Scholar]
- 9. Drexler HG, Sagawa K, Menon M, Minowada J. 1986. Phenotyping of malignant hematopoietic cells. II. Reactivity pattern of myeloid monoclonal antibodies with emphasis on MCS‐2. Leuk Res 10:17–23. [DOI] [PubMed] [Google Scholar]
- 10. Pombo de Oliveira MS, Matutes E, Rani S, Morilla R, Catovsky D. 1988. Early expression of MCS2 (CD13) in the cytoplasm of blast cells from acute myeloid leukemia. Acta Haematol 80:61–64. [DOI] [PubMed] [Google Scholar]
- 11. Look AT, Ashmun RA, Shapiro LH, et al. Report on the CD13 (aminopeptidase N) cluster workshop In: Knapp W, Dorken B, Gilks WR, et al., editors. Leucocyte typing IV. White cell differentiation antigens. New York: Oxford University Press; p 784–787. [Google Scholar]
- 12. Ortuno F, Soler J, Vilella R, Bordes R, Guanyabens C, Rubiol E, Pujol‐Moix N. 1990. Immunophenotype of blast cells in acute myelofibrosis. Leuk Res 14:849–856. [DOI] [PubMed] [Google Scholar]
- 13. Finstad CL, Cordon‐Cardo C, Bander NH, Whitmore WF, Melamed MR, Old LJ. 1985. Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci USA 82:2955–2959. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Sobol RE, Royston I, Lebien TW, Minowada J, Anderson K, Davey FR, Cuttner J, Schiffer C, Ellison RR, Bloomfield CD. 1985. Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies. Blood 65:730–735. [PubMed] [Google Scholar]
- 15. Stass S, Mirro J. 1985. Unexpected heterogeneity in acute leukemia: mixed lineages and lineage switch. Hum Pathol 16:864–866. [DOI] [PubMed] [Google Scholar]
- 16. Nakase K, Kita K, Shiku H, Tanaka I, Nasu K, Dohy H, Kyo T, Tsutani H, Kamada N. 1996. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms. Am J Clin Pathol 105:761–768. [DOI] [PubMed] [Google Scholar]
- 17. Putti MC, Rondelli R, Cocito MG, Arico M, Sainata L, Conter V, Guglielmi C, Cantu‐Rajnoldi A, Consolini R, Pession A, Zanesco L, Masera G, Biondi A, Basso G. 1998. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP—ALL 88‐91 studies. Blood 92(3):795–801. [PubMed] [Google Scholar]
- 18. Carbone A, Gloghini A, Volpe R, Pinto A. 1993. KP1 (CD68)‐positive large‐cell lymphomas: a histopathologic and immunophenotypic characterization of 12 cases. Hum Pathol 24(8):886–896. [DOI] [PubMed] [Google Scholar]
- 19. Ohsaka A, Sato N, Imai Y, Hirai S, Oka Y, Kikuchi M, Takahashi A. 1996. Multiple gastric involvement by myeloid antigen CD13‐positive non‐secretory plasma cell leukemia. Br J Haematol 92:134–136. [DOI] [PMC free article] [PubMed] [Google Scholar]